No connection

Search Results

ABBV vs CPHI

ABBV
AbbVie Inc.
NEUTRAL
Price
$219.26
Market Cap
$387.52B
Sector
Healthcare
AI Confidence
68%
CPHI
China Pharma Holdings, Inc.
BEARISH
Price
$0.63
Market Cap
$25.5M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
ABBV
163.63
CPHI
--
Forward P/E
ABBV
15.42
CPHI
--
P/B Ratio
ABBV
-146.66
CPHI
0.43
P/S Ratio
ABBV
6.5
CPHI
6.15
EV/EBITDA
ABBV
15.27
CPHI
-18.34

Profitability

Gross Margin
ABBV
71.46%
CPHI
-3.18%
Operating Margin
ABBV
35.5%
CPHI
-97.86%
Profit Margin
ABBV
4.0%
CPHI
-76.92%
ROE
ABBV
137.96%
CPHI
-20.91%
ROA
ABBV
9.59%
CPHI
-8.41%

Growth

Revenue Growth
ABBV
9.1%
CPHI
8.1%
Earnings Growth
ABBV
-88.7%
CPHI
--

Financial Health

Debt/Equity
ABBV
--
CPHI
0.17
Current Ratio
ABBV
0.72
CPHI
0.32
Quick Ratio
ABBV
0.47
CPHI
0.09

Dividends

Dividend Yield
ABBV
3.05%
CPHI
--
Payout Ratio
ABBV
490.15%
CPHI
0.0%

AI Verdict

ABBV NEUTRAL

The Advanced Deterministic Scorecard reveals a mixed health profile with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite robust operating margins and consistent revenue growth, the company faces significant headwinds from negative earnings growth, an extremely high P/E ratio, and a dangerously elevated payout ratio. Strong historical price performance and analyst buy sentiment are counterbalanced by bearish insider activity and deteriorating profitability trends. The stock appears to trade at a substantial premium to its intrinsic value, suggesting limited margin of safety.

Strengths
High operating margin (35.50%) indicating strong pricing power and cost control
Consistent revenue growth (9.10% YoY) outpacing sector average
Strong track record of earnings surprises (22 out of 25 quarters beat estimates)
Risks
Extremely high P/E ratio (163.63) vs forward P/E (15.42), suggesting potential overvaluation on trailing basis
Earnings growth collapsing (YoY: -88.70%, Q/Q: -88.10%) indicating severe profitability deterioration
Unsustainable dividend payout ratio (490.15%) threatening dividend security
CPHI BEARISH

CPHI exhibits severe financial distress, anchored by a weak Piotroski F-Score of 2/9 and a critical liquidity crisis. The company is operating with a negative gross margin (-3.18%), meaning it loses money on every product sold before operating expenses are even considered. With a current ratio of 0.32 and a quick ratio of 0.09, the firm lacks the liquid assets to cover its short-term obligations. This fundamental collapse is reflected in a catastrophic 5-year price decline of 99.8%.

Strengths
Low Debt/Equity ratio (0.17) suggests limited long-term leverage
Modest year-over-year revenue growth of 8.10%
Trading at a discount to book value (P/B 0.43)
Risks
Critical liquidity risk with a Current Ratio of 0.32
Negative gross margins indicate a non-viable core business model
Severe profitability collapse (Operating Margin -97.86%)

Compare Another Pair

ABBV vs CPHI: Head-to-Head Comparison

This page compares AbbVie Inc. (ABBV) and China Pharma Holdings, Inc. (CPHI) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile